Total Funding
54
44
Total FundingSeries D raised
Growth Score
-15 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
8045
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Acquired by 
Bristol-Myers Squibb
Aron Knickerbocker: Co-FounderPast Role: Five Prime Therapeutics, Vice President, Business Development- Susan Moran: Chief Medical Officer
About the Company
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.
Women Founded
